
Teva to sell Allergan’s UK & Ireland generics business for $770m
pharmafile | October 6, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Allergan, Teva
Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
The company completed its acquisition of Allergan’s generics business in August for $40.5 billion. It is now selling the UK and Ireland branches of the business to India’s Intas Pharmaceuticals. The sale was part of Teva’s deal with the European Commission to get approval for the acquisition of Allergan’s generics arm, which is known as Actavis Generics.
Greenhill & Co is Teva’s financial adviser, while Rothschild & Co is advising Intas. According to Teva, the sale is expected to close in the next three months.
Matt Fellows
Related Content

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …





